For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development | 4,552 | 3,329* | ||
| General and administrative | 4,729 | 3,853* | ||
| Total operating expenses | 9,281 | 7,181 | ||
| Loss from operations | -9,281 | -7,181* | ||
| Change in fair value of warrant derivative | 0 | -38* | ||
| Fair value loss from standby equity purchase agreement (sepa arrangement) | - | -97* | ||
| Foreign exchange loss | -6 | -26* | ||
| Interest income | 44 | 97* | ||
| Total other income, net | 38 | 11* | ||
| Loss before income taxes | - | -7,170* | ||
| Income tax expense | - | 20* | ||
| Net loss | -9,243 | -7,190* | ||
| Translation adjustments | 0 | -34* | ||
| Comprehensive loss | -9,243 | -7,224 | ||
| Basic EPS | -0.08 | -0.075 | ||
| Diluted EPS | -0.08 | -0.075 | ||
| Basic Average Shares | 112,292,579 | 95,857,147 | ||
| Diluted Average Shares | 112,292,579 | 95,857,147 | ||
ONCOLYTICS BIOTECH INC (ONCY)
ONCOLYTICS BIOTECH INC (ONCY)